These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35577257)

  • 21. Meropenem pharmacokinetics during extracorporeal membrane oxygenation and continuous haemodialysis: a case report.
    Saito J; Shoji K; Oho Y; Aoki S; Matsumoto S; Yoshida M; Nakamura H; Kaneko Y; Hayashi T; Yamatani A; Capparelli E; Miyairi I
    J Glob Antimicrob Resist; 2020 Sep; 22():651-655. PubMed ID: 32417590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.
    Al-Shaer MH; Neely MN; Liu J; Cherabuddi K; Venugopalan V; Rhodes NJ; Klinker K; Scheetz MH; Peloquin CA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetics of Vancomycin in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study).
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Cho YJ; Corley A; Diehl A; Gilder E; Jakob SM; Kim HS; Levkovich BJ; Lim SY; McGuinness S; Parke R; Pellegrino V; Que YA; Reynolds C; Rudham S; Wallis SC; Welch SA; Zacharias D; Fraser JF; Shekar K; Roberts JA;
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0137721. PubMed ID: 34633852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation.
    Fratoni AJ; Kois AK; Gluck JA; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2024 May; 79(5):1118-1125. PubMed ID: 38517465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy.
    Pavia K; Hambrick HR; Paice K; Tang P; Punt N; Kaplan J; Goldstein SL; Vinks AA; Mizuno T; Tang Girdwood S
    J Antimicrob Chemother; 2023 Sep; 78(9):2140-2147. PubMed ID: 37466170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Randomized Pharmacokinetic and Pharmacodynamic Evaluation of Every 8-Hour and 12-Hour Dosing Strategies of Vancomycin and Cefepime in Neurocritically ill Patients.
    Kassel LE; Van Matre ET; Foster CJ; Fish DN; Mueller SW; Sherman DS; Wempe MF; MacLaren R; Neumann RT; Kiser TH
    Pharmacotherapy; 2018 Sep; 38(9):921-934. PubMed ID: 29906310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imipenem Population Pharmacokinetics: Therapeutic Drug Monitoring Data Collected in Critically Ill Patients with or without Extracorporeal Membrane Oxygenation.
    Chen W; Zhang D; Lian W; Wang X; Du W; Zhang Z; Guo D; Zhang X; Zhan Q; Li P
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study.
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Cho YJ; Corley A; Diehl A; Gilder E; Jakob SM; Kim HS; Levkovich BJ; Lim SY; McGuinness S; Parke R; Pellegrino V; Que YA; Reynolds C; Rudham S; Wallis SC; Welch SA; Zacharias D; Fraser JF; Shekar K; Roberts JA;
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0143821. PubMed ID: 34460303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.
    Nicasio AM; Ariano RE; Zelenitsky SA; Kim A; Crandon JL; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1476-81. PubMed ID: 19188394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
    Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation.
    Lee DH; Kim HS; Park S; Kim HI; Lee SH; Kim YK
    Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
    Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
    Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.
    Jaruratanasirikul S; Vattanavanit V; Wongpoowarak W; Nawakitrangsan M; Samaeng M
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):735-747. PubMed ID: 32886347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling.
    Kang S; Yang S; Hahn J; Jang JY; Min KL; Wi J; Chang MJ
    J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients.
    An G; Creech CB; Wu N; Nation RL; Gu K; Nalbant D; Jimenez-Truque N; Fissell W; Patel PC; Fishbane N; Watanabe A; Rolsma S; Kirkpatrick CMJ; Landersdorfer CB; Winokur P
    J Antimicrob Chemother; 2023 Jun; 78(6):1460-1470. PubMed ID: 37071586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of daptomycin in critically ill patients receiving extracorporeal membrane oxygenation.
    Zhang LC; Li QY; Zhang YQ; Shan TC; Li Y; Li YH; Han H; Qin WD; Guo HP; Zhao W; Tang BH; Chen XM
    J Antimicrob Chemother; 2024 Jul; 79(7):1697-1705. PubMed ID: 38814793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation.
    Kang S; Jang JY; Hahn J; Kim D; Lee JY; Min KL; Yang S; Wi J; Chang MJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.